Louisiana State Employees Retirement System Acquires New Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Louisiana State Employees Retirement System bought a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGTGet Rating) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 9,700 shares of the company’s stock, valued at approximately $370,000.

Other hedge funds also recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in shares of Fulgent Genetics by 318.5% in the 1st quarter. JPMorgan Chase & Co. now owns 78,457 shares of the company’s stock worth $4,896,000 after acquiring an additional 59,711 shares during the last quarter. Raymond James & Associates lifted its stake in Fulgent Genetics by 42.9% during the first quarter. Raymond James & Associates now owns 14,944 shares of the company’s stock worth $933,000 after purchasing an additional 4,486 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Fulgent Genetics by 25.8% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 24,905 shares of the company’s stock worth $1,554,000 after buying an additional 5,106 shares during the period. Citigroup Inc. grew its stake in shares of Fulgent Genetics by 3.6% in the first quarter. Citigroup Inc. now owns 20,152 shares of the company’s stock valued at $1,258,000 after buying an additional 702 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Fulgent Genetics by 7.6% in the 1st quarter. Bank of Montreal Can now owns 6,551 shares of the company’s stock valued at $410,000 after buying an additional 461 shares during the period. Hedge funds and other institutional investors own 43.22% of the company’s stock.

Fulgent Genetics Stock Performance

FLGT stock opened at $31.00 on Thursday. The company’s 50 day moving average price is $33.73 and its 200 day moving average price is $42.58. The firm has a market capitalization of $912.58 million, a price-to-earnings ratio of 3.56 and a beta of 1.55. Fulgent Genetics, Inc. has a fifty-two week low of $28.53 and a fifty-two week high of $83.17.

Fulgent Genetics (NASDAQ:FLGTGet Rating) last posted its quarterly earnings results on Monday, November 7th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.13. Fulgent Genetics had a net margin of 33.82% and a return on equity of 22.10%. The company had revenue of $105.66 million during the quarter, compared to analysts’ expectations of $103.70 million. Equities analysts forecast that Fulgent Genetics, Inc. will post 4.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on FLGT. Piper Sandler cut Fulgent Genetics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $65.00 to $40.00 in a report on Thursday, December 8th. Raymond James initiated coverage on shares of Fulgent Genetics in a research note on Friday, November 18th. They issued an “outperform” rating and a $45.00 price objective for the company. StockNews.com started coverage on shares of Fulgent Genetics in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, Credit Suisse Group decreased their price target on shares of Fulgent Genetics from $65.00 to $50.00 and set an “outperform” rating for the company in a research report on Monday, November 14th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.00.

Fulgent Genetics Company Profile

(Get Rating)

Fulgent Genetics, Inc, together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests.

See Also

Want to see what other hedge funds are holding FLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulgent Genetics, Inc. (NASDAQ:FLGTGet Rating).

Institutional Ownership by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.